Manufacturers' early commitment to emerging Asian markets key to long-term success -- HIMA's Zavada.
This article was originally published in The Gray Sheet
DEVICE FIRMS' COMMITMENT TO EMERGING ASIAN MARKETS during early years of economic fluctuation should pay off in the long-term as the markets enter periods of sustained growth, Terri Zavada, the Health Industry Manufacturers Association's director for global strategy and analysis, said during a June 27 briefing in Washington, D.C. Companies "definitely have to be there in the formative stages in order to be a really strong player when the market" begins to stabilize, Zavada said. HIMA held the briefing to announce release of its 1996 "Emerging Markets Report."
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.